Please assess the completion status of the following clinical trial:

Trial Title: Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of informed consent before any trial specific procedures.~2. Diagnosed with type 2 diabetes mellitus based on the current American Diabetes Association guidelines.~3. Aged \>18 and \<80 years~4. Body Mass Index ≥23~5. HbA1c 48-85mmol/mol (last known result within in the previous 6 months)~6. Blood pressure \<145/90mmHg. Office BP at screening visit will be used however if this is above the inclusion criteria then the 24 hour or 16 hour recording at screening visit will be used to confirm that in the opinion of the PI the BP is adequately controlled.~7. Echocardiographic left ventricular (LV) hypertrophy (defined as an LV mass index of \>115g/m2 for men and \>95g/m2 for women indexed to body surface area or \>48g/m2.7 or \>44g/m2.7 when indexed to height) within the previous 6 months.~8. Women of childbearing potential must agree to take precautions to avoid pregnancy throughout the trial and for 4 weeks after intake of the last dose.~Exclusion Criteria:~1. 1. Any condition that in the opinion of the investigator may render the participant unable to complete the trial including non CV disease (e.g. active malignancy).~2. Participants with type 1 diabetes mellitus~3. Participants who have previously had an episode of diabetic ketoacidosis.~4. Serum Potassium or Sodium results outwith the normal range~5. Diagnosis of clinical heart failure~6. History of human immunodeficiency virus~7. LV systolic dysfunction (LVEF \<45%) (last known result within in the previous 6 months)~8. eGFR \<45ml/min (last known result within in the previous month)~9. Known liver function tests \>3 times upper limit of normal (based on last measures and documented laboratory measurement in the previous 6 months)~10. Body weight \>150Kg (unable to fit into a MRI scanner)~11. Contraindications to MRI (e.g. claustrophobia, metal implants, penetrative eye injury or exposure to metal fragments in eye requiring medical attention)~12. Past or current treatment with any SGLT2 inhibitor~13. Allergy to any SGLT2 inhibitor or lactose or galactose intolerance~14. Current treatment with loop diuretic~15. Currently receiving long term (\>30 consecutive days) treatment with an oral steroid~16. Pregnant or breast feeding participants~17. Involvement in the planning and/or conduct of the trial (applies to Astra Zeneca or representative staff and/or staff at the trial site).~18. Participation in another interventional study (other than observational trials and registries) within 30 days before visit 1.~19. Individuals considered at risk for poor protocol or medication compliance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Active (Type: ACTIVE_COMPARATOR): Dapagliflozin 10mg once daily for 12 months
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 10mg once daily for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).